Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;4(4):125-129.
doi: 10.1016/j.prnil.2016.09.002. Epub 2016 Oct 8.

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

Sonja Cabarkapa  1 , Marlon Perera  1 , Shannon McGrath  1 , Nathan Lawrentschuk  2
Affiliations
Review

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

Sonja Cabarkapa et al. Prostate Int. 2016 Dec.

Abstract

Background: Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk prediction of prostate cancer. Its use in the setting of prostate cancer screening has been controversial due to the risk of over diagnosis and over treatment.

Objective: Within Australia, there are inconsistent recommendations surrounding the use of PSA screening in clinical practice. In light of the 2016 PSA-screening guidelines by the major Australian health authorities, the current review aims to highlight the controversies and objectively outline the current recommendations within Australia.

Discussion: Health-care authorities across Australia have issued conflicting guidelines for prostate cancer screening culminating in confusion amongst health care practitioners and members of the public alike. A general consensus is held by other countries across the globe but differences amongst the specific details in how to best employ a PSA screening program still exist.

Keywords: Guidelines; Prostate cancer; Prostate-specific antigen; Screening.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Trends in prostate-specific antigen testing.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer in Australia 2014: actual incidence data from 1982 to 2011 and mortality data from 1982 to 2012 with projections to 2014. Asia Pac J Clin Oncol. 2015;11:208–220. - PubMed
    1. Prostate Cancer Statistics: Australian Institute of Health and Welfare; 2015 [Internet]. [cited 2016 Feb 24]. Available from: https://prostate-cancer.canceraustralia.gov.au/statistics.
    1. Australian Institute of Health and Welfare . AIHW; Canberra: 2014. Cancer in Australia: an overview.http://www.aihw.gov.au/publication-detail/?id=60129550047 Cancer series no. 90 [Internet] Available from:
    1. McGrath S., Christidis D., Perera M., Vela I., Manning T., Lawrentschuk N. Prostate cancer biomarkers: are we hitting the mark? Prostate Int. 2016;4:130–135. - PMC - PubMed
    1. Perera M., Manning T., Finelli A., Lawrentschuk N. Management of men with previous negative prostate biopsy. Curr Opin Urol. 2016;26:481–487. - PubMed